ACCP Pulmonary PRN

The Pulmonary PRN advances the pharmacotherapy of pulmonary disorders through the promotion of excellence in education, research, and clinical practice

[ACCP Pulmonary PRN @ACCPpulmPRN]

Pulm PRN: we want to hear from YOU. Let us know your accomplishments for the upcoming PRN Report: https://t.co/wFTOEZY4Ab

[CHEST® Journal @journal_CHEST]

ICU Management of the Patient With Fibrotic Interstitial Lung Disease

Read more in #journal_CHESTCritCare: https://t.co/INGqgQeE07
#MedEd #JournalCHEST

[CHEST @accpchest]

ICU Management of the Patient With Fibrotic Interstitial Lung Disease

Read more in #journal_CHESTCritCare: https://t.co/498HKRxavB
#MedEd #JournalCHEST

[GOLD COPD @GOLD_COPD]

The 2025 GOLD Report and Pocket Guide are now available on Amazon! Click on the link below to order your own printed copy of the most up to date guidance in COPD diagnosis, management and prevention.
To order: https://t.co/E1moMlGp1L

[Pharmacotherapy @PharmacoJournal]

This systematic review aimed to summarize the efficacy and safety of cannabinoids to treat obstructive sleep apnea https://t.co/C1JJ2otiYr

[ACCP Pulmonary PRN @ACCPpulmPRN]

Do you know the answer to this CF-related trivia question? Swipe to see the answer!

#Pharmacy #ACCP #Pulmonary #Pulm

[ACCP Pulmonary PRN @ACCPpulmPRN]

🌟Taking a Breather: Our annual Pulmonary PRN newsletter is here! Dive into key PRN activities you won’t want to miss at the upcoming 2024 ACCP Annual Meeting. Read all about it: https://t.co/OBFeJ4p5iL
@ACCP

[ACCP Pulmonary PRN @ACCPpulmPRN]

@ACCP Congrats!!

[U.S. FDA @US_FDA]

Today, we granted emergency use authorization for an updated Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. https://t.co/xzOuIpmSPe

[Global Initiative for Asthma (GINA) @ginasthma]

Confirming asthma diagnosis once inhaled corticosteroids (ICS) are started can be difficult. If asthma is well-controlled, stepping down ICS may help with diagnosis. Start with assessment – see highlighted section GINA 2024 Box 1-5. Full explanation at https://t.co/Cm9ADXmsOb

[FDA Tobacco @FDATobacco]

Teachers, get free resources and lesson plans for talking with your students about the dangers of vaping: https://t.co/9nSnlirwg9

[Don Sin @donsin4]

A simple question in severe #asthma: once a patient's asthma is controlled on an anti-IL-5 biologic, do they have to be on this med forever or can they be "weaned off"? If latter, what is the protocol? The answers are found in OPTIMAL @ERSpublications
https://t.co/9zPfYYT2lo

[CHEST @accpchest]

The latest journal CHEST® How I Do It shows how to approach diagnosis and management for patients with interstitial lung disease (#ILD). Read more in the August @journal_CHEST issue: https://t.co/3i1UA16lKD
#MedEd #JournalCHEST

[CHEST @accpchest]

New downloadable flowcharts outline the suggested treatment for patients presenting with malignant or nonmalignant central airway obstruction, as detailed in a new CHEST guideline.

Download the flowcharts and read the full guideline: https://t.co/qG1RSppRgX

[ACCP Pulmonary PRN @ACCPpulmPRN]

Attending #ACCPAM24 and want to catch-up with your Pulm PRN pals? Let us know your availability for a social event! https://t.co/w5S69YCMK0

[ACCP Pulmonary PRN @ACCPpulmPRN]

Are you ready to explore residency programs? Join the SNPhA x ACCP Virtual Residency Showcase on Nov. 12 & 14. Connect with program directors for FREE from your home! Open to all students and residents. Don't miss out! https://t.co/V2dS7kobYK
#PharmRes #SNPhA #ACCP

[ACCP Pulmonary PRN @ACCPpulmPRN]

It's that time of year! Let the Pulm PRN know your accomplishments: https://t.co/pw9uCbyjnQ

[The Lancet Respiratory Medicine @LancetRespirMed]

New: Cluster analysis of blood biomarkers to identify molecular patterns in #pulmonaryfibrosis

These findings support the presence of pulmonary fibrosis endotypes with the potential to guide targeted therapy development

Available free here: https://t.co/h4XcvIGxEk

[ACCP @ACCP]

The Journal of the American College of Clinical Pharmacy is currently providing free access to research and scholarly methods until July 14. Access the collection here: https://t.co/5MBrKLNtyE
@JACCPJournal

[Global Initiative for Asthma (GINA) @ginasthma]

GINA 2024 clarifies that assessment of symptom control should not be limited to the last 4 weeks, and emphasizes that assessing symptom control is not enough. Risk factors for exacerbations, including past exacerbations, must also be assessed. https://t.co/Cm9ADXmsOb